Management of post-BCG lymphadenitis.
D001500:BCG Vaccine / Q000009:adverse effects*; D004917:Erythromycin / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007538:Isoniazid / Q000627:therapeutic use; D008198:Lymph Nodes / Q000473:pathology; D008199:Lymphadenitis / Q000209:etiology*; D013307:Streptomycin / Q000627:therapeutic use; D014376:Tuberculosis / Q000517:prevention & control
D001500:BCG Vaccine; D004917:Erythromycin; D007538:Isoniazid; D013307:Streptomycin